<DOC>
	<DOCNO>NCT00635336</DOCNO>
	<brief_summary>The purpose study evaluate safety clinical efficacy novel vaccination advance bladder cancer .</brief_summary>
	<brief_title>Novel Peptide Vaccination Patients With Advanced Bladder Cancer</brief_title>
	<detailed_description>DEP domain contain 1 ( DEPDC1 ) M phase phosphoprotein 1 ( MPHOSPH1 ) identify use genome-wide expression profile analysis use cDNA microarray previous study . We determine HLA-A*2402 restrict epitope peptide derive DEPDC1 , DEPDC1-9-294 , MPHOSPH1 , MPHOSPH1-9-278 . These epitope show strong IFN-g production stimulate appropriate target express appropriate protein HLA-A*2402 . Furthermore , vaccinate peptide , specific CTLs determine vaccination . Therefore focus safety efficacy novel vaccination advance bladder cancer patient already show resistance standard chemotherapy radiotherapy .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>DISEASE CHARACTERISTICS 1. advance bladder cancer already show resistance standard treatment 2 . Protein expression MPHOSPH1 DEPDC1 tumor PATIENTS CHARACTERISTICS 1 . Patients show resistance standard chemotherapy radiotherapy 2 . Histological diagnosis transitional cell carcinoma 3 . HLAA*2402 4 . ECOG performance status 0 1 5 . Age ≥ 20 year , ≤80 year 6 . WBC≥ 2,000/mm³ , ≤15000/mm³ Platelet count ≥ 75000/mm³ AST , ALT ≤150 IU/l Total bilirubin ≤ 3.0 mg/dl Creatinine ≤ 3.0 mg/dl 7. lesion bladder cancer must express MPHOSPH1 DEPDC1 8 . Able willing give valid write informed consent 1 . Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) 2 . Breastfeeding 3 . Patients willing childbearing ( Refusal inability use effective mean contraception ) 4 . Serious infection require antibiotic 5 . Concomitant treatment steroid immunosuppressing agent 6 . Other malignancy difficult control . 7 . Decision unsuitableness principal investigator physicianincharge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Epitope peptide</keyword>
	<keyword>CTL</keyword>
	<keyword>Advanced bladder cancer</keyword>
	<keyword>Vaccination</keyword>
	<keyword>advanced bladder cancer show resistance standard treatment</keyword>
</DOC>